| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/20/2011 | US20110014186 Arylsulfonamide-based matrix metalloprotease inhibitors |
| 01/20/2011 | US20110014185 Methods involving graf polypeptides |
| 01/20/2011 | US20110014183 Mcam modulation and uses thereof |
| 01/20/2011 | US20110014181 Microneedle Delivery Device and Methods of Using Same |
| 01/20/2011 | US20110014177 Methods for Enhancing Physical and Mental Energy |
| 01/20/2011 | US20110014176 Compounds and method for reducing uric acid |
| 01/20/2011 | US20110014175 Stimulation of the synthesis of the activity of an isoform of lysl oxidase-like loxl for stimulating the formation of elastic fibres |
| 01/20/2011 | US20110014174 Lysozyme, A Novel Vasodilator of Sepsis that can be inhibited by a Peroxidase and Hydroxyl Radical Scavengers |
| 01/20/2011 | US20110014165 Thymidylate Kinase Mutants and Uses Thereof |
| 01/20/2011 | US20110014154 Aromatic Heterocyclic Fused Indolobenzadiazepine HCV NS5B Inhibitors |
| 01/20/2011 | US20110014151 Macromolecule conjugate |
| 01/20/2011 | US20110014141 Topical agent for dermatological use |
| 01/20/2011 | US20110014137 Methods for protecting the skin from radiation insults |
| 01/20/2011 | US20110014134 Suspension aerosol formulations of pharmaceutical products |
| 01/20/2011 | US20110014133 Compositions and Methods to Treat Asthma |
| 01/20/2011 | US20110014127 Methods for measuring a patient response upon administration of a drug and compositions thereof |
| 01/20/2011 | US20110014126 Use of vitamin d receptor agonists and precursors to treat fibrosis |
| 01/20/2011 | US20110014124 Targeted atherosclerosis treatment |
| 01/20/2011 | US20110014123 RNA interference mediating small RNA molecules |
| 01/20/2011 | US20110014121 Modulators of cxcr7 |
| 01/20/2011 | US20110014118 Nanotherapeutic colloidal metal compositions and methods |
| 01/20/2011 | US20110011961 Granules comprising a beta-lactam antibiotic |
| 01/20/2011 | US20110011392 Olopatadine nasal spray regimen for children |
| 01/20/2011 | US20110010817 Articles of Manufacture Releasing an Active Ingredient |
| 01/20/2011 | DE102010026686A1 Hemmung des Überlebens von Pankreaskrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of pancreatic cancer by cyclohexenone from Antrodia camphorata |
| 01/20/2011 | DE102009033621A1 Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen Separating layers for pharmaceutical preparations for prevention of interactions between drugs and pharmaceutically-technological auxiliaries |
| 01/20/2011 | DE102009033396A1 Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung Aqueous solution and gelatinized composition comprising a phosphodiesterase-5 inhibitor, and related procedures and use |
| 01/20/2011 | DE102009033392A1 Heterocyclische Verbindungen als Autotaxin-Inhibitoren II Heterocyclic compounds as inhibitors Autotaxin II |
| 01/20/2011 | DE102009033208A1 Aminopyridinderivate Aminopyridine |
| 01/20/2011 | CA2805033A1 Methods of increasing liver proliferation |
| 01/20/2011 | CA2803061A1 Vaccines and compositions against streptococcus pneumoniae |
| 01/20/2011 | CA2778517A1 Substituted triazole and imidazole derivatives as gamma secretase modulators |
| 01/20/2011 | CA2768505A1 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer |
| 01/20/2011 | CA2768452A1 Material and process for incorporation of low dosage active pharmaceutical ingredients and use thereof |
| 01/20/2011 | CA2768383A1 Pellets formulation |
| 01/20/2011 | CA2768377A1 Process for the preparation of o-desmethyl venlafaxine and intermediate for use therein |
| 01/20/2011 | CA2768370A1 Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
| 01/20/2011 | CA2768368A1 Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| 01/20/2011 | CA2768356A1 Compositions comprising a cholinesterase inhibitor for treating cognitive disorders |
| 01/20/2011 | CA2768342A1 Humic substances and therapeutic uses thereof |
| 01/20/2011 | CA2768338A1 Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
| 01/20/2011 | CA2768329A1 Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction |
| 01/20/2011 | CA2768291A1 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase |
| 01/20/2011 | CA2768241A1 A mechanism and method for regulating glycogen synthase kinase 3 (gsk3)-related kinases |
| 01/20/2011 | CA2768237A1 Treatment method |
| 01/20/2011 | CA2768236A1 (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| 01/20/2011 | CA2768210A1 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt |
| 01/20/2011 | CA2768169A1 Aminopyridine derivatives for the treatment of tumors and inflammatory diseases |
| 01/20/2011 | CA2768104A1 Combination of a sodium-proton exchanger inhibitor and of a dihydro-1,3,5-triazine amine derivative |
| 01/20/2011 | CA2768095A1 Heterocyclic compounds as autotaxin inhibitors ii |
| 01/20/2011 | CA2768081A1 Anti-influenza agents |
| 01/20/2011 | CA2768050A1 Use of at least one omega-3 fatty acid and of at least one polyphenol for the endogenous synthesis of eicosapentanoic acid and docosahexanoic acid |
| 01/20/2011 | CA2768018A1 Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
| 01/20/2011 | CA2768015A1 Tazarotene derivatives |
| 01/20/2011 | CA2768006A1 Olopatadine nasal spray regimen for children |
| 01/20/2011 | CA2767992A1 2 - [[[2 -[(hydroxyacetyl) amino]- 4 -pyridinyl] methyl] thio]- n -[4 - (trifluoromethoxy) phenyl]- 3 -pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof |
| 01/20/2011 | CA2767987A1 Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof |
| 01/20/2011 | CA2767971A1 Treating patients with intravenous ibuprofen |
| 01/20/2011 | CA2767911A1 Compounds as hypoxia mimetics, and compositions, and uses thereof |
| 01/20/2011 | CA2767894A1 Apoptosis signal-regulating kinase inhibitors |
| 01/20/2011 | CA2767889A1 Antibacterial oral composition |
| 01/20/2011 | CA2767887A1 Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| 01/20/2011 | CA2767833A1 N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen |
| 01/20/2011 | CA2767764A1 Heterocyclic compound and use thereof |
| 01/20/2011 | CA2767642A1 Lupeol-type triterpene derivatives as antivirals |
| 01/20/2011 | CA2767614A1 Fusidic acid dosing regimens for treatment of bacterial infections |
| 01/20/2011 | CA2767585A1 Pyridin-4-yl derivatives |
| 01/20/2011 | CA2767453A1 2,3-fluorinated glycosides as neuraminidase inhibitors and their use as anti-virals |
| 01/20/2011 | CA2767372A1 3-phenoxymethylpyrrolidine compounds |
| 01/20/2011 | CA2767335A1 Pet food compositions including a sustained-release lipoic acid and methods of manufacture and use thereof |
| 01/20/2011 | CA2767233A1 5-ht3 receptor modulators, methods of making, and use thereof |
| 01/20/2011 | CA2767089A1 Pyrrolopyridine inhibitors of kinases |
| 01/20/2011 | CA2766883A1 Tricyclic indole-derived spiro derivatives as crth2 modulators |
| 01/20/2011 | CA2766874A1 Tetrazole derivatives |
| 01/20/2011 | CA2766100A1 Pyrimidinones as pi3k inhibitors |
| 01/20/2011 | CA2765942A1 Flavin derivatives |
| 01/20/2011 | CA2765921A1 Imidazole derivatives as mglur5 antagonists |
| 01/20/2011 | CA2765621A1 Crystalline freebase forms of a biphenyl compound |
| 01/20/2011 | CA2764927A1 Exo-s-mecamylamine method, use, and compound for treatment |
| 01/20/2011 | CA2764906A1 Gpr119 agonists |
| 01/20/2011 | CA2764603A1 Process for producing crystals of polymorphic 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid by poor-solvent addition method |
| 01/20/2011 | CA2738151A1 Eye drop with difluprednate for macular edema treatment |
| 01/19/2011 | EP2275573A1 Antibodies for treating and diagnosing gastric adenocarcinoma |
| 01/19/2011 | EP2275563A2 Transgenic plant-based methods for plant insect pests using RNAi |
| 01/19/2011 | EP2275562A2 Transgenic plant-based methods for plant insect pests using RNAi |
| 01/19/2011 | EP2275548A1 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 01/19/2011 | EP2275546A2 Enzymatic DNA molecules |
| 01/19/2011 | EP2275544A2 Genes and polypeptides relating to human colon cancers |
| 01/19/2011 | EP2275543A2 Compositions and their uses directed to hepcidin |
| 01/19/2011 | EP2275538A1 Novel dna capable of being amplified by pcr with high selectivity and high efficiency |
| 01/19/2011 | EP2275535A1 Animal cells and processes for the replication of influenza viruses |
| 01/19/2011 | EP2275450A1 Treatment with anti-ERBB2 antibodies |
| 01/19/2011 | EP2275438A1 Glucagon-like peptide-2 analogs |
| 01/19/2011 | EP2275430A1 Hemifumarate of a pyrazole derivative |
| 01/19/2011 | EP2275425A1 Novel crystalline forms of temozolomide |
| 01/19/2011 | EP2275424A1 Doripenem crystallization process |
| 01/19/2011 | EP2275421A1 Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction |
| 01/19/2011 | EP2275420A1 Therapeutic agents useful for treating pain |
| 01/19/2011 | EP2275419A2 A lubiprostone crystal, its preparation process and its use |
| 01/19/2011 | EP2275416A1 Biologically active methylene blue derivatives |